Health Affairs This Week places listeners at the center of health policy’s proverbial water cooler. Join host Jeff Byers, editors from Health Affairs Publishing, and guests as they discuss health policy’s most pressing news and trends.
Hello and welcome to Health Affairs This Week. I'm your host, Jeff Beyers. We are recording on 11/10/2026. Today on the pod, we are talking about how CMS late last week finalized a framework for the Medicare drug price negotiation program for 2029. It was a little later than expected, that rule.
Jeff Byers:To discuss the rule, we have Rachel Sachs, a law professor from the Washington University and St. Louis School of Law, back on the program once again. Rachel, welcome back.
Rachel Sachs:Thank you. It's always good to be here.
Jeff Byers:Yeah, yeah. It's been a bit, and I, you know, we've had this rule drop. This is an emergency pod. I wanted to make sure we had someone that could really break down the drug pricing negotiation program, what it means, what is this framework. So, very excited to have you on the program.
Rachel Sachs:Thank you. And as you noted, there is a lot of policy here to discuss. I'm happy to get into it.
Jeff Byers:So let's get into it. The rule, it sets policies for the Medicare drug price negotiation program beginning with prices effective in 2029. So that's a couple of years away. But for listeners, you know, that may not be familiar with this, what's the headline regarding this rule and what's the framework?
Rachel Sachs:So there's two main procedural points that listeners should keep in mind here. The first is that this rule, as you noted, is intended to govern the fourth cycle of the negotiation program for 2029. But this is actually the first cycle to be implemented through rulemaking. So the Inflation Reduction Act, which included the Medicare drug price negotiation program, was passed in 2022, but Congress told CMS that it could use guidance to implement the negotiation program for 2026, 2027, and 2028. So this is the first year we're seeing the agency engaging in rulemaking.
Rachel Sachs:And then second main point here, which is related, is that the vast majority of the policies presented in the 2029 rule are not new. Most of them have been worked out by CMS in previous guidance cycles. CMS already has experience implementing most of them, and manufacturers have experience working with them as well. So although this rule represents an important procedural step forward for the program, there are fewer new substantive policies than might have been expected.
Jeff Byers:Okay. So what can we expect? You know, this is for 2029. That's a couple of years away, as noted. Is there anything we can expect from the program in 'twenty seven or 'twenty eight regarding the Medicare drug price negotiation program's impact on health care costs?
Rachel Sachs:Absolutely. And there's reason to think that we might learn different things from those two different years. So remember that for 2026, CMS was able to select for negotiation just 10 drugs covered by Medicare Part D. For 2027, CMS selected 15 drugs covered under Part D, and CMS obtained lower prices for 2027 than they did for 2026. The apples to apples number that we have is CMS' projection of what net spending would have been absent the negotiation program.
Rachel Sachs:And for 2026, they said that the negotiated prices would have represented 22% lower net spending. But for 2027, they would have represented 44% lower net spending. Some of that is due to the mix of the drugs that were selected for some types and ages of drugs, but some of it is the learning the administration did between the 2026 and 2027 cycles and the bargains the agency sought to strike. 2028 will be different because CMS selected at least initially 15 drugs, some of which are covered under Part D, but some of which are payable under Part B. They're administered by physicians.
Rachel Sachs:And the negotiation period for those drugs has ended, and CMS has until the end of this month to release those prices. But as we're recording, they have not yet been made public. So I'm very interested in learning more about how CMS approached the negotiations for these Part B products. It's also going to be interesting to see how the negotiations for some of even the Part D products compare with the negotiations of other similar products that CMS has negotiated for in past years. I do want to take a step back here and just note that although the negotiation program is important in terms of its relationship to health care costs, it is just one small program in a much broader set of drug pricing initiatives and the Medicare and Medicaid programs federal government spending as a whole.
Rachel Sachs:So this is a program enabling CMS to negotiate within Medicare the prices of a limited number of drugs, which have been on the market for many years and are still very costly to the Medicare program. So we can talk about the impact of this program or the combination of the IRA reforms on healthcare costs, but it is part of this broader conversation.
Jeff Byers:I wanted to talk about overall drug pricing efforts, but focusing still on the Medicare drug price negotiation program. You know, you and co author Christy Martin wrote an article in Forefront in June of this year around the time the proposed rule was announced. The article is titled Administration Releases Drug Price Negotiation Program Proposed Rule for 2029. Very, very little headline. I'll put links in the show notes so listeners can find it.
Jeff Byers:In this article, you note three policy changes in the proposed rule, including a change to CMS' treatment of fixed combination drugs. So I think I know what a combination drug might be based on the name combination drug, but, you know, teach me what a combination drug is and what's the change of treatment.
Rachel Sachs:Sure, sure. So this is a complex topic, and I apologize to expert listeners for some simple some simplifications. But essentially a combination drug is a drug that combines more than one active ingredient or active moiety. So imagine that you have drug A and drug B and they are approved and marketed separately. And then you combine them into one pill and you approve and market them as a combination.
Rachel Sachs:People may be familiar with this from different therapeutic contexts. So one is HIV, where a number of different compounds might be combined into a single pill, but each of them is biologically active against the disease state in question, though maybe they have a different mechanism of action. And what CMS had been doing was to say that if the active ingredient in drug A is eligible for negotiation, we will not aggregate the separate product that contains the combination of drug A and drug B with the drug that is the product that is only drug A for negotiation purposes. But since the guidance for the 2026 cycle of the program, CMS has been signaling its intention to reconsider whether that should be true in all cases. So although this is a new policy for 2029, it's not a surprise to people who've been watching the issue closely.
Jeff Byers:So what did CMS change?
Rachel Sachs:So for 2029, they had proposed and now they've finalized a narrow modification to this general rule. And CMS will now aggregate together a fixed combination drug with one of its component parts when an additional active ingredient or moiety is added that creates a new formulation and enables an alternative route of administration for the co administered active ingredients or moieties. The statute tells CMS to aggregate data across dosage forms and strengths of a drug together for purposes of the negotiation program, including new formulations of a drug such as an extended release formulation. So CMS's modification is tied to that statutory aggregation instruction. And the reason this matters is that the manufacturers of two of the highest expenditure drugs under Medicare Part B, Keytruda and Opdivo, have reformulated their products in subcutaneous form where they combine the active ingredients in those drugs with hyaluronidase, which is an absorption enhancing adjuvant, which isn't separately approved for the treatment of cancer.
Rachel Sachs:So it's a little different than the HIV example I gave a moment ago. And CMS had referred to the possibility of these being separate products for the negotiation program as a program integrity risk given the statutory aggregation language and the potential policy consequences. And so they developed this narrow modification to respond to it. It had been expected that Keytruda and Opdivo could be selected for the 2028 cycle of the program, but the 2025 reconciliation law expanded the negotiation program's orphan drug exemption in a way that delayed the eligibility of selection for these drugs to the 2029 cycle. So it became less urgent to resolve it last year.
Jeff Byers:There's a new temporary price floor for certain products. Is that correct?
Rachel Sachs:Yes. And this is also not a surprise because the statute tells CMS to create the floor for 2029 and 2030. So the IRA had a three year exemption from negotiation for qualifying small biotech drugs 2026, 2027, 2028. And then for 2029 and 2030, the statute envisioned that this exemption would be replaced by a temporary floor below which the negotiated price can't fall. Now, there are some operational challenges here.
Rachel Sachs:So, for example, what should CMS do if the floor below which the negotiated price can't fall is above the statutory ceiling, which the negotiated price cannot exceed. And there are some situations in which this might occur, and CMS proposed methods to calculate an adjusted ceiling, which they modified slightly between the proposed and the final rule.
Jeff Byers:Okay. So all in all, as you mentioned, the Medicare drug price negotiation program is, you know, one piece in the overall drug pricing policy efforts. For that particular program, what might you see the impact being in 2030 when it comes to prices or costs?
Rachel Sachs:That's right. So the Medicare drug price negotiation program is just one drug pricing reform within the Inflation Reduction Act, which also redesigned the Medicare Part D program to create an out of pocket cap for seniors, which didn't previously exist, to include an inflation rebate program in Medicare. And the Part D redesign has phased in in terms of increasing the generosity of the benefit for seniors. And the effect of that is to increase costs to the Medicare program. But the negotiation program is still in the process of phasing in.
Rachel Sachs:We've just had the negotiated prices for the first 10 drugs take effect. So CMS projected after the IRA was passed that the negotiation program would reduce Medicare Part B expenditures relatively quickly, but that Medicare Part D expenditures would go up through 2030, after which Part D expenditures would start going down as the negotiation program fully phased in just in terms of CMS's projections. So it can both be the case that the negotiation program is lowering expenditures for some of these high cost drugs in Part D, but also that the increase in the generosity of the benefit is increasing overall Part D expenditures.
Jeff Byers:Okay. So time will tell where the net net might be.
Rachel Sachs:I think that's right.
Jeff Byers:Okay, so how is this program fitting into overall drug pricing efforts? You know, earlier this year we had Stacy Ducicina on the pod to discuss the Trump administration's The Great Health Care Plan. It was referred to in that episode as the Great Health Care Vision Board. A large section of this plan was to quote unquote lower drug prices. So do you get a sense of like how that vision is shaping up as we look to close out the year?
Rachel Sachs:Yeah. People should certainly go and listen to Stacy's podcast, which is terrific. And and one note here is that there is this almost alphabet soup of models that we've seen coming out of the administration. Generous, GLOBE, Guard, the Bridge and Balance demonstration programs, etcetera. And one note is that those other drug pricing initiatives come mostly from executive action.
Rachel Sachs:They involve the different deals that the administration is announcing with pharmaceutical companies. And in terms of where those other efforts are, Christy Martin and I have written separately for Health Affairs Forefront about the administration's recent finalization of the GLOBE model for achieving most favored nation discounts in Medicare Part B, and that final rule substantially narrowed the reach of the model from its proposed version. The final rule for GUARD has been sent to OMB, but as a recording, it has not been released publicly. Under generous, we still don't actually know publicly which products are included in generous or what the combination of price and non price terms is. We do know that all 50 states have signed on to get more information about the options available to them under the program, but we don't know yet which states are actually going to sign supplemental rebate agreements for which drugs and how much savings there might be.
Rachel Sachs:The Bridge demonstration program is off to a strong start, stronger than some observers had anticipated. But one question we're still waiting to learn about is how Bridge will interact with the negotiation program in 2027, where the manufacturer of semaglutide agreed to make the drug available through Bridge at a price below the price it agreed to through the negotiation program for 2027. There's some interesting dynamics and operational challenges that we're looking to learn more about.
Jeff Byers:Well, thanks for that. The tale of change is long, especially when it comes to bureaucracy and policy. Rachel Sachs, as we close out, any last thoughts on the final rule that we've been discussing?
Rachel Sachs:I always like to help people understand the timing here and also the pressure that career staff are under because they are really doing a lot of very challenging work under very difficult circumstances. And here, I'm not even talking about the more general pressure on civil servants and efforts to fire large numbers of federal employees, many of whom work at HHS. So the negotiated prices for the first cycle of the program went into effect earlier this year in 2026. CMS is working to implement that first cycle of the program and also get ready for the negotiated prices for 2027 to go into effect in January. At the same time, CMS has just wrapped up the negotiation period for drugs selected for 2028, which as I noted, includes these drugs payable under Part B.
Rachel Sachs:So they have to think ahead to the challenges of operationalizing this program within Part B for the first time. And over the summer, we actually had a separate draft guidance document on that topic. And at the same time, CMS is working on rulemaking for 2029 and will soon begin the process of selecting drugs for that cycle. So the career staff are trying to juggle four different cycles of the program at once, each of which is in a different phase of its implementation and each of which has different challenges associated with it.
Jeff Byers:Well, Sachs, thanks again for joining us today on Health Affairs This Week. If you, the listener, enjoyed this conversation, please send it to a friend and we will see you later this week.